NCT01938833View on ClinicalTrials.gov

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 18, 2016

Study Completion Date

December 8, 2016

Conditions

HER2-negative Breast CancerInflammatory Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast Cancer

Interventions

DRUG

Romidepsin

DRUG

Abraxane

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT01938833 - Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | Biotech Hunter | Biotech Hunter